

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

1. (currently amended): A method for delivery of a chemical or biological entity to a target tissue or cellular surface of a patient comprising:

binding a molecule to said tissue or cellular surface, wherein said molecule comprises at least one reactive group that reacts with groups present on said surface, and at least one signaling molecule;

attaching said chemical or biological entity to said signaling molecule by means of a recognition molecule, wherein said recognition molecule is specific for said signaling molecule, wherein the recognition molecule and the signaling molecule have an affinity for each other; ~~and~~

wherein said reactive group binds ~~ionically~~, covalently, ~~non-covalently or by hydrogen bonding~~ to said tissue or cellular surface, and

wherein said delivery steps can be effected under conditions tolerable *in vivo*.

2. (original): The method of Claim 1, wherein said molecule further comprises a polymer that masks adhesive information inherent to the tissue or cellular surface.

3. (previously presented): The method of Claim 1, wherein said tissue is vascular tissue and where the modified tissue ~~or cellular~~ surface provides a target for subsequent delivery of the chemical or biological entity.

4. (canceled)

5. (currently amended): The method of Claim 1, wherein said reactive group is selected from the group consisting of an ester, anhydride, isocyanate, aldehyde, tosylate, tresylate, epoxide, ~~maleimide~~ maleimide and a N-hydroxy-succinimide.

6. (withdrawn): The method of Claim 1, wherein the reactive group is a cycloester, cycloanhydride or isocyanate.

7. (currently amended): The method of Claim 1, wherein the reactive group is in the molecule N-hydroxy-succinimide-biotin (NHS-biotin) is N-hydroxy-succinimide.

8. (original): The method of Claim 2, wherein the polymer is polyethylene glycol.

9. (original): The method of Claim 8, wherein the reactive group is N-hydroxy-succinimide.
10. (original): The method of Claim 1, wherein delivery is of a chemical entity.
11. (previously presented): The method of Claim 10, wherein said chemical entity is a pharmaceutical agent in a form selected from the group consisting of molecular, ~~liposomal~~liposomal, micellar and solid particulate.
12. (original): The method of Claim 11, wherein said pharmaceutical agent is an anti-thrombotic agent, an antimitotic agent, or a chemotherapeutic agent.
13. (withdrawn): The method of Claim 10, wherein said chemical agent is a contrast or imaging agent.
14. (withdrawn): The method of Claim 1, wherein delivery is of a biological entity.
15. (withdrawn): The method of Claim 14, wherein said biological entity is a modified or unmodified cell.
16. (withdrawn): The method of Claim 15, wherein said biological entity is a chemically modified cell.
17. (withdrawn): The method of Claim 15, wherein said biological entity is a genetically modified cell.
18. (withdrawn): The method of Claim 1, wherein delivery is of a viral vector, non-viral vector or naked nucleic acid sequence.
19. (previously presented): The method of Claim 1, wherein said signaling molecule/recognition molecule combination is selected from the group consisting of biotin/avidin; ligand/receptor; antibody/antigen; primary antibody/secondary antibody; protein A/fc IgG1; and protein c/fc IgG1.
20. (canceled)
21. (withdrawn): A tissue surface that has been modified by binding to the surface a molecule, wherein said molecule comprises at least one reactive group that reacts with groups present on said surface, and at least one signaling molecule.
22. (withdrawn): A cellular surface that has been modified by binding to the surface a molecule, wherein said molecule comprises at least one reactive group that reacts with groups present on said surface, and at least one signaling molecule.

23. (withdrawn): The method of Claim 1, wherein said delivery steps can be effected in from about 1 to about 2 minutes, and wherein the groups present on the tissue or cellular surface are selected from the group consisting of amines and hydroxyl groups.

24. (previously presented): The method of Claim 1, wherein said reactive group is selected from the group consisting of an ester, anhydride, isocyanate, aldehyde, tosylate, tresylate, epoxide, maleimide and a N-hydroxy-succinimide, and mixtures thereof and the signaling molecule/recognition molecule is selected from the group consisting of biotin/avidin; ligand/receptor; antibody/antigen; primary antibody/secondary antibody; protein A/fc IgG1; and protein c/fc IgG1.

25. (withdrawn): The method of Claim 1, wherein the chemical or biological entity is a microbubble ultrasound contrasting agent, which can be delivered locally.

26. (previously presented): The method of Claim 1, wherein the delivery of the chemical or biological entity is local or systemic.

27. (previously presented): The method of Claim 1, wherein the delivery of the chemical or biological entity is local.

28. (previously presented): The method of Claim 1, wherein the reactive group binds covalently.

29. (withdrawn): The method of Claim 1, wherein the signaling molecule includes any group that will function to signal the recognition molecule absent compatibility problems.